Partner Fund Management L.P. cut its holdings in Irhythm Technologies Inc (NASDAQ:IRTC) by 51.9% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 235,941 shares of the company’s stock after selling 254,489 shares during the quarter. Partner Fund Management L.P.’s holdings in Irhythm Technologies were worth $22,334,000 at the end of the most recent quarter.
Several other hedge funds have also bought and sold shares of the stock. Eaton Vance Management grew its holdings in shares of Irhythm Technologies by 37.6% in the third quarter. Eaton Vance Management now owns 61,796 shares of the company’s stock valued at $5,850,000 after purchasing an additional 16,884 shares in the last quarter. GSA Capital Partners LLP purchased a new position in shares of Irhythm Technologies in the third quarter valued at $533,000. Bellevue Group AG grew its holdings in shares of Irhythm Technologies by 51.7% in the third quarter. Bellevue Group AG now owns 69,661 shares of the company’s stock valued at $6,594,000 after purchasing an additional 23,740 shares in the last quarter. Quantbot Technologies LP boosted its stake in Irhythm Technologies by 44.3% during the third quarter. Quantbot Technologies LP now owns 8,609 shares of the company’s stock worth $814,000 after buying an additional 2,641 shares during the period. Finally, Credit Suisse AG boosted its stake in Irhythm Technologies by 8.1% during the third quarter. Credit Suisse AG now owns 22,590 shares of the company’s stock worth $2,138,000 after buying an additional 1,699 shares during the period. 99.38% of the stock is owned by hedge funds and other institutional investors.
IRTC has been the subject of several recent analyst reports. BidaskClub raised shares of Irhythm Technologies from a “hold” rating to a “buy” rating in a research note on Friday, August 24th. Chardan Capital initiated coverage on shares of Irhythm Technologies in a research note on Thursday, September 6th. They set a “buy” rating and a $117.00 price objective for the company. Canaccord Genuity lifted their price objective on shares of Irhythm Technologies from $93.00 to $100.00 and gave the stock a “buy” rating in a research note on Thursday, September 13th. Morgan Stanley lifted their price objective on shares of Irhythm Technologies from $92.00 to $95.00 and gave the stock an “overweight” rating in a research note on Thursday, October 11th. Finally, Zacks Investment Research raised shares of Irhythm Technologies from a “hold” rating to a “buy” rating and set a $86.00 price objective for the company in a research note on Saturday, October 27th. Five analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $93.13.
NASDAQ IRTC opened at $72.49 on Thursday. The company has a quick ratio of 4.69, a current ratio of 4.79 and a debt-to-equity ratio of 0.51. The firm has a market cap of $1.79 billion, a price-to-earnings ratio of -54.74 and a beta of 1.97. Irhythm Technologies Inc has a 52 week low of $50.37 and a 52 week high of $98.37.
Irhythm Technologies (NASDAQ:IRTC) last posted its quarterly earnings data on Tuesday, October 30th. The company reported ($0.43) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.02. The company had revenue of $38.10 million during the quarter, compared to analyst estimates of $35.87 million. Irhythm Technologies had a negative net margin of 33.79% and a negative return on equity of 62.85%. Irhythm Technologies’s quarterly revenue was up 52.2% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.29) earnings per share. Analysts predict that Irhythm Technologies Inc will post -1.86 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This piece was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at https://sportsperspectives.com/2018/12/06/partner-fund-management-l-p-sells-254489-shares-of-irhythm-technologies-inc-irtc.html.
Irhythm Technologies Company Profile
iRhythm Technologies, Inc, a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. The company offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias.
Further Reading: How to Invest in the Dividend Aristocrat Index
Want to see what other hedge funds are holding IRTC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Irhythm Technologies Inc (NASDAQ:IRTC).
Receive News & Ratings for Irhythm Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Irhythm Technologies and related companies with MarketBeat.com's FREE daily email newsletter.